Specifically, mRNA levels of PSMB5 in MM cells collected from patients who underwent 6-cycle of intensive bortezomib-based treatment were about 5-fold higher relative to before bortezomib treatment, with no PSMB5 mutation [Table 2]. This evidence concerns the gene PSMB5 and Miyoshi myopathy.